NasdaqGS:RIGLBiotechs
Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High‑Earnings Narrative
Rigel Pharmaceuticals (RIGL) opened 2026 with Q1 revenue of US$58.8 million and basic EPS of US$0.47, alongside trailing 12‑month revenue of US$299.8 million and basic EPS of US$20.08, set against very large year over year earnings growth and higher net profit margins in the latest trailing figures. Over recent quarters the company has seen revenue move from US$57.6 million in Q4 2024 to US$53.3 million in Q1 2025, US$101.7 million in Q2 2025, US$69.5 million in Q3 2025 and US$69.8 million in...